Organon and Samsung Bioepis launch Humira biosimilar Hadlima in the U.S.
Organon & Co. (OGN) and partner Samsung Bioepis Co. Ltd. said Wednesday they have launched their Humira biosimilar Hadlima in the U.S. The move comes after Humira, AbbVie' Inc.'s (ABBV) rheumatoid arthritis drug that is one of the best selling biopharma products of all time, was opened to biosimilar competition on July 1 after losing its U.S. exclusivity earlier this year. Jersey City, N.J.-based Organon said Hadlima comes with a patient support program, including co-pay support. "As the largest loss-of-exclusivity event in pharmaceutical history, this is a singular moment for the US health care system to embrace biosimilars," Organon CEO Kevin Ali said in a statement. Hadlima is available for a range of illnesses, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis. It's available as a carton with two prefilled pens or syringes at a list price of $1,038, equal to an 85% discount over the list priced of Humira, said the companies. Organon's stock was slightly higher premarket but has fallen 26% in the year to date, while the S&P 500 has gained 16%.
-Ciara Linnane
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
07-05-23 0740ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
4 New Stocks to Buy With Catalysts for Future Gains
-
Markets Brief: Q2 Earnings Season Begins With the Banks
-
Six Sports Betting and iGaming Stocks Trading at a Discount
-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
The 10 Best Dividend Stocks
-
3 Smaller-Company Stocks the Best Fund Managers Are Buying
-
SolarEdge Stock Is Down 74% In 2024. Is It a Buy or a Sell?
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities